Suet-Feung Chin

Associate Scientist

Research Group Home Page:: Caldas Group

Work address:: Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre Robinson Way Cambridge CB2 0RE

Publications:: Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.

E-pub date: 31 Jul 2019; Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.

E-pub date: 28 Feb 2019; PDLIM2 is a marker of adhesion and β-catenin activity in triple-negative breast cancer.

E-pub date: 28 Feb 2019; Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.

E-pub date: 31 Jan 2019; Genome-wide association study of germline variants and breast cancer-specific mortality.

E-pub date: 31 Jan 2019; Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA.

E-pub date: 31 Dec 2018; Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study.

E-pub date: 31 Jul 2018; Molecular Classification of Breast Cancer.

E-pub date: 01 Jul 2018; Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers.

E-pub date: 01 Jun 2018; Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element.

E-pub date: 31 May 2018; αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer.

E-pub date: 17 May 2018; Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort.

E-pub date: 07 Mar 2018; Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts.

E-pub date: 05 Jan 2018; Body mass index and breast cancer survival: a Mendelian randomization analysis.

E-pub date: 01 Dec 2017; The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

E-pub date: 25 Aug 2017; Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.

E-pub date: 15 Jul 2017; Intersect-then-combine approach: improving the performance of somatic variant calling in whole exome sequencing data using multiple aligners and callers.

E-pub date: 18 Apr 2017; Subtype-specific micro-RNA expression signatures in breast cancer progression.

E-pub date: 01 Sep 2016; Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer.

E-pub date: 31 Aug 2016; Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes.

E-pub date: 06 Jun 2016; The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

E-pub date: 10 May 2016; Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

E-pub date: 05 Jan 2016; Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.

E-pub date: 04 Nov 2015; BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.

E-pub date: 31 Oct 2015; Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

E-pub date: 31 Aug 2015; Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

E-pub date: 01 Jun 2015; Identification of novel genetic markers of breast cancer survival.

E-pub date: 31 May 2015; Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.

E-pub date: 23 Apr 2015; Common germline polymorphisms associated with breast cancer-specific survival.

E-pub date: 22 Apr 2015; Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53.

E-pub date: 31 Mar 2015; A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer.

E-pub date: 31 Jan 2015; BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells.

E-pub date: 09 Jan 2015; Genome-driven integrated classification of breast cancer validated in over 7,500 samples.

E-pub date: 28 Aug 2014; Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.

E-pub date: 01 Aug 2014; TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.

E-pub date: 01 Jul 2014; 22p * development of a brca1-like signature in triple negative breast cancers within the rather (rational therapy for breast cancer) consortium.

E-pub date: 31 May 2014; Processed pseudogenes acquired somatically during cancer development.

E-pub date: 09 Apr 2014; TOX3 mutations in breast cancer.

E-pub date: 31 Aug 2013; Master regulators of FGFR2 signalling and breast cancer risk.

E-pub date: 31 Aug 2013; A prognostic gene signature for metastasis-free survival of triple negative breast cancer patients.

E-pub date: 31 Aug 2013; The shaping and functional consequences of the microRNA landscape in breast cancer.

E-pub date: 16 May 2013; Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.

E-pub date: 02 May 2013; Analysis of circulating tumor DNA to monitor metastatic breast cancer.

E-pub date: 28 Mar 2013; Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor.

E-pub date: 21 Feb 2013; Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes.

E-pub date: 22 Dec 2012; Copynumber: Efficient algorithms for single- and multi-track copy number segmentation.

E-pub date: 04 Nov 2012; Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer.

E-pub date: 31 Oct 2012; Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling.

E-pub date: 24 Oct 2012; Calling sample mix-ups in cancer population studies.

E-pub date: 31 Aug 2012; The landscape of cancer genes and mutational processes in breast cancer.

E-pub date: 16 May 2012; The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.

E-pub date: 18 Apr 2012; Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers.

E-pub date: 18 Apr 2012; The clonal and mutational evolution spectrum of primary triple-negative breast cancers.

E-pub date: 04 Apr 2012; MNK2 inhibits eIF4G activation through a pathway involving serine-arginine-rich protein kinase in skeletal muscle.

E-pub date: 14 Feb 2012; Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.

E-pub date: 04 Jan 2012; Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma.

E-pub date: 31 Oct 2011; ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium.

E-pub date: 31 Mar 2011; Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

E-pub date: 30 Jun 2010; Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas.

E-pub date: 31 May 2010; Genomic gain of 5p15 leads to over-expression of Misu (NSUN2) in breast cancer.

E-pub date: 01 Mar 2010; The pitfalls of platform comparison: DNA copy number array technologies assessed.

E-pub date: 08 Dec 2009; A metadata approach for clinical data management in translational genomics studies in breast cancer.

E-pub date: 30 Nov 2009; The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene.

E-pub date: 19 Nov 2009; Germline CDH1 deletions in hereditary diffuse gastric cancer families.

E-pub date: 01 May 2009; High-resolution array CGH clarifies events occurring on 8p in carcinogenesis.

E-pub date: 07 Oct 2008; PMC42, a breast progenitor cancer cell line, has normal-like mRNA and microRNA transcriptomes.

E-pub date: 31 Aug 2008; ESR1 gene amplification in breast cancer: a common phenomenon?

E-pub date: 31 Jul 2008; Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer.

E-pub date: 06 May 2008; High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.

E-pub date: 01 May 2008; Regulation of p53 tetramerization and nuclear export by ARC.

E-pub date: 26 Dec 2007; MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype.

E-pub date: 31 Aug 2007; High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer.

E-pub date: 31 Aug 2007; Co-amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event.

E-pub date: 31 May 2007; Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers.

E-pub date: 22 Mar 2007; Cross-platform array comparative genomic hybridization meta-analysis separates hematopoietic and mesenchymal from epithelial tumors.

E-pub date: 01 Mar 2007; EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.

E-pub date: 31 Oct 2003; A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples.

E-pub date: 01 Oct 2003; Cell cycle checkpoint evasion and protracted cell cycle arrest in X-irradiated small-cell lung carcinoma cells.

E-pub date: 01 Sep 1999; Show all Hide all

Suet-Feung Chin

Associate Scientist

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.

Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.

PDLIM2 is a marker of adhesion and β-catenin activity in triple-negative breast cancer.

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.

Genome-wide association study of germline variants and breast cancer-specific mortality.

Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA.

Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study.

Molecular Classification of Breast Cancer.

Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers.

Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element.

αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer.

Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort.

Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts.

Body mass index and breast cancer survival: a Mendelian randomization analysis.

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.

Intersect-then-combine approach: improving the performance of somatic variant calling in whole exome sequencing data using multiple aligners and callers.

Subtype-specific micro-RNA expression signatures in breast cancer progression.

Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer.

Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes.

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.

BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.

Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Identification of novel genetic markers of breast cancer survival.

Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.

Common germline polymorphisms associated with breast cancer-specific survival.

Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53.

A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer.

BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells.

Genome-driven integrated classification of breast cancer validated in over 7,500 samples.

Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.

TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.

22p * development of a brca1-like signature in triple negative breast cancers within the rather (rational therapy for breast cancer) consortium.

Processed pseudogenes acquired somatically during cancer development.

TOX3 mutations in breast cancer.

Master regulators of FGFR2 signalling and breast cancer risk.

A prognostic gene signature for metastasis-free survival of triple negative breast cancer patients.

The shaping and functional consequences of the microRNA landscape in breast cancer.

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.

Analysis of circulating tumor DNA to monitor metastatic breast cancer.

Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor.

Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes.

Copynumber: Efficient algorithms for single- and multi-track copy number segmentation.

Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer.

Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling.

Calling sample mix-ups in cancer population studies.

The landscape of cancer genes and mutational processes in breast cancer.

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.

Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers.

The clonal and mutational evolution spectrum of primary triple-negative breast cancers.

MNK2 inhibits eIF4G activation through a pathway involving serine-arginine-rich protein kinase in skeletal muscle.

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.

Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma.

ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium.

Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas.

Genomic gain of 5p15 leads to over-expression of Misu (NSUN2) in breast cancer.

The pitfalls of platform comparison: DNA copy number array technologies assessed.

A metadata approach for clinical data management in translational genomics studies in breast cancer.

The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene.

Germline CDH1 deletions in hereditary diffuse gastric cancer families.

High-resolution array CGH clarifies events occurring on 8p in carcinogenesis.

PMC42, a breast progenitor cancer cell line, has normal-like mRNA and microRNA transcriptomes.

ESR1 gene amplification in breast cancer: a common phenomenon?

Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer.

High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.

Regulation of p53 tetramerization and nuclear export by ARC.

MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype.

High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer.

Co-amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event.

Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers.

Cross-platform array comparative genomic hybridization meta-analysis separates hematopoietic and mesenchymal from epithelial tumors.

EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.

A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples.

Cell cycle checkpoint evasion and protracted cell cycle arrest in X-irradiated small-cell lung carcinoma cells.